A recent study found more resistance to the antiretroviral medicine tenofovir than had previously been reported, with 20% resistance to tenofovir in patients with treatment failure in Europe and over 50% resistance in patients with treatment failure in sub-Saharan Africa... The study underlines the importance of rapidly identifying treatment failure through routine measurement of viral load suppression—this is the basis of the third pillar of UNAIDS’ 90–90–90 treatment target, that 90% of people accessing HIV treatment have suppressed viral loads.
09 February 2016 | UNAIDS
Even people who are adherent to their medication regimens may experience occasional “blips” in their viral loads, experience viral rebound or maintain a steady, if low, viral load above undetectable levels. To understand why some people struggle to achieve or remain undetectable, we spoke with Keith Henry, MD, an HIV specialist at Hennepin County Medical Center who has more than 25 years of experience caring for people with HIV.
06 January 2016 | BETA blog
A recent study published in The Lancet HIV provides evidence that HIV maintenance therapy with a provider-selected boosted protease inhibitor (PI) regimen does not increase the risk of drug resistance and thus preserves future treatment options. But questions remain as to whether PI-monotherapy could be a clinically useful and relevant long-term HIV maintenance strategy.
10 December 2015 | BETA blog
A Columbia University study evaluated whether HIV-infected children in South Africa who had achieved viral suppression with one antiretroviral treatment could transition to efavirenz-based therapy, the recommended drug for children older than three years, without risk of viral failure. The researchers reported that the treatment program resulted in excellent sustained virological control.
06 November 2015 | Eurekalert Inf Dis
The new BHIVA treatment guidelines recommend: "All individuals with HIV... are reviewed promptly by an
HIV specialist and offered immediate ART." See http://www.aidsmap.com/page/2979458/ for a summary of the main recommendations.
26 September 2015 | BHIVA
ViiV Healthcare today announced 24-week data from the Phase IIIb/IV STRIIVING study, an open-label study evaluating the efficacy, safety and tolerability of switching from an antiretroviral therapy (ART) to the once-daily, fixed-dose dolutegravir-based regimen, Triumeq® (abacavir/dolutegravir/lamivudine) in virologically suppressed adults with HIV-1.
23 September 2015 | Viiv Healthcare press release
Recent data suggested that retreatment HIV drug resistance in sub-Saharan Africa was associated with a nearly fourfold increase in switching to second-line ART, but did not influence mortality or AIDS-related events.
11 August 2015 | Healio
On 14 January 2015, NHS England published the long awaited policy on dolutegravir and the fixed dose combination (FDC) of dolutegravir/abacavir/3TC (Triumeq). The London prescribing guidelines for first-line therapy have also been updated to include dolutegravir and Triumeq.
14 January 2015 | HIV i-Base
Diagnosing HIV and other infectious diseases presents unique challenges in remote locations that lack electric power, refrigeration, and appropriately trained health care staff. To address these issues, researchers have developed a low-cost, electricity-free device capable of detecting the DNA of infectious pathogens, including HIV-1.
10 December 2014 | Science Daily
HIV drug regimens that do not include efavirenz are effective as first-line antiretroviral therapy, a new American clinical trial found. The finding is important for patients who are not eligible for treatment with efavirenz, including women considering becoming pregnant and patients with a history of severe psychiatric disorders.
07 October 2014 | Science Daily